Vemurafenib

Generic Name: Vemurafenib

Brand Names: Zelboraf

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₁₈ClF_₂N_₃O_₃S

CAS Number: 918504-65-1

Unique Ingredient Identifier: 207SMY3FQT

Background: Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...

Indication: Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...

Associated Conditions: Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease

Associated Therapies: -

Clinical Trials

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC

Phase 2

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: Vemurafenib
Drug: Cobimetinib
Drug: Atezolizumab

First Posted Date: 2014-12-01

Last Posted Date: 2021-02-03

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 47

Registration Number: NCT02303951

Locations: 🇩🇪
University hospital Tübingen, Tübingen, Germany
🇫🇷
Department of Dermatology, University Hospital of Nantes, Nantes, France
🇫🇷
Hopital Saint-Louis Hopitaux Universitaires Saint-Louis Laboisiere Fernand-Widal, Paris, France

and more 4 locations

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX induction regimen
Drug: Fluoropyrimidine (5-FU/LV or capecitabine)
Drug: Cetuximab
Drug: Trastuzumab
Drug: Bevacizumab
Drug: Pertuzumab
Drug: Vemurafenib
Drug: Atezolizumab
Drug: Cobimetinib
Drug: 5-FU/LV
Drug: Capecitabine

First Posted Date: 2014-11-14

Last Posted Date: 2024-05-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1044

Registration Number: NCT02291289

Locations: 🇦🇷
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología, Buenos Aires, Argentina
🇧🇪
Institut Jules Bordet X, Brussels, Belgium
🇧🇪
Hospital Erasme, Bruxelles, Belgium

and more 151 locations

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Phase 2

Terminated

Conditions: Active Melanoma Brain Metastases

Interventions: Drug: Cobimetinib
Drug: Vemurafenib

First Posted Date: 2014-09-03

Last Posted Date: 2017-10-12

Lead Sponsor: Melissa Burgess, MD

Target Recruit Count: 5

Registration Number: NCT02230306

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Mohammed Milhem, MD, Iowa City, Iowa, United States
🇺🇸
Anna Pavlick, MD, New York, New York, United States

and more 3 locations

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: irinotecan hydrochloride
Drug: vemurafenib

First Posted Date: 2014-06-17

Last Posted Date: 2020-12-30

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 106

Registration Number: NCT02164916

Locations: 🇺🇸
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 756 locations

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Phase 1

Withdrawn

Conditions: Recurrent Melanoma
Stage IV Melanoma
Tumors Metastatic to Brain

Interventions: Drug: Vemurafenib
Radiation: Whole-brain radiation therapy (WBRT)
Radiation: Radiosurgery (SRS)

First Posted Date: 2014-05-23

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT02145910

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers with the BRAF Inhibitor Vemurafenib: a Pilot Study

Not Applicable

Completed

Conditions: Thyroid Carcinoma

Interventions: Drug: Vemurafenib
Device: serial 124I PET/CT
Drug: thyrotropin alpha

First Posted Date: 2014-05-22

Last Posted Date: 2024-11-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT02145143

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2

Completed

Conditions: Bladder Cancer
Neoplasms
Solid Tumors
Biliary Cancer
Salivary Cancer

Interventions: Drug: Atezolizumab
Drug: Trastuzumab
Drug: Vemurafenib
Drug: Vismodegib
Drug: Alectinib
Drug: Erlotinib
Drug: Pertuzumab
Drug: Cobimetinib

First Posted Date: 2014-03-19

Last Posted Date: 2024-07-23

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 673

Registration Number: NCT02091141

Locations: 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 57 locations

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

Phase 2

Terminated

Conditions: Metastatic Melanoma (Carrying BRAF V600 Mutation)

Interventions: Drug: Dabrafenib
Drug: Vemurafenib

First Posted Date: 2014-01-31

Last Posted Date: 2022-12-19

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 8

Registration Number: NCT02052193

Locations: 🇩🇪
Department of Dermatology, Tuebingen, BW, Germany

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

Phase 2

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: Acitretin
Drug: Vemurafenib

First Posted Date: 2014-01-30

Last Posted Date: 2018-12-26

Lead Sponsor: University of Arizona

Target Recruit Count: 2

Registration Number: NCT02050321

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Vemurafenib
Drug: Cobimetinib

First Posted Date: 2014-01-14

Last Posted Date: 2022-10-27

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 24

Registration Number: NCT02036086

Locations: 🇨🇦
The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
🇨🇦
Royal Victoria Hospital, Montreal, Quebec, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy